Forrester To Recognise Return On Integration Honours And Programme Of The Year Winners At Its B2B Summit EMEA 2024
3.9.2024 12:00:00 EEST | Business Wire | Press release
Forrester (Nasdaq: FORR) will recognise Shell Fleet Solutions as the 2024 recipient of its B2B Return On Integration (ROI) Honours at B2B Summit EMEA, taking place October 7–9, 2024, in London. The organisation will be recognised for delivering impactful customer experiences (CX) and aligning its marketing and sales functions to drive company growth. Forrester will also honour this year’s B2B Programme of the Year (POY) winners, Infocert and Cora Systems, for bringing customer-focus across marketing and sales functions.
B2B Summit EMEA is the leading event for B2B marketing and sales leaders to explore new research insights, frameworks, and best practices to achieve cross-functional alignment, and evolve their go-to-market approaches to implement revenue process transformation. At the event, honourees will present how they have implemented functional alignment centered on creating customer value and growth and launched integrated global campaigns to achieve business outcomes.
This year’s ROI Honours winner, Shell Fleet Solutions, a global leader in business mobility, adopted an automated, data-driven marketing approach to better serve the needs of its customers. In its keynote session, Shell Fleet Solutions will discuss how the firm combined account, contact and buying group behavioural data in an automated way, and used calculated insights to better understand its customers’ behaviours, improve sales and marketing alignment, and increase customer value.
“To sustain long-term growth, we moved from a lead-centric to an opportunity-centric marketing approach. This allowed us to obtain insights into buying groups and better understand our overall customers’ behaviour,” said Angela Scaueru, global customer dialogue manager at Shell Fleet Solutions. “We took two important steps to drive value. First, we recognised intent signals from contacts and bundled these signals at the account level to share with Sales. Secondly, we implemented an automated modular content engine to deliver personalisation based on both account and contact behaviour. This optimised our customer experience, identified new sales opportunities, and enhanced sales and marketing alignment.”
The Programme of the Year winners will also share their success stories at B2B Summit EMEA:
- Infocert will discuss how it has transformed its lead management process by improving alignment between sales and marketing.
- Cora Systems will highlight how it has increased the quality and quantity of its leads by transforming its pipeline generation strategy.
“This year’s ROI Honours and Programme of the Year winners are perfect examples of how strong cross-functional alignment can positively impact company performance and growth,” said Simon Daniels, principal analyst at Forrester. “At B2B Summit EMEA, attendees will benefit from hearing Shell Fleet Solutions, Infocert and Cora Systems share their success stories on stage, as well as attending a series of interactive sessions that provide insight into how industry peers are revolutionising their B2B strategy.”
Resources:
- Register to attend B2B Summit EMEA.
- Follow @Forrester and #ForrB2BSummit for updates.
- Learn how Forrester Decisions for B2B Marketing Executives, Forrester Decisions for B2B Sales, and Forrester Decisions for Product Management can help drive functional alignment.
About Forrester
Forrester (Nasdaq: FORR) is one of the most influential research and advisory firms in the world. We help leaders across technology, customer experience, digital, marketing, sales, and product functions use customer obsession to accelerate growth. Through Forrester’s proprietary research, consulting, and events, leaders from around the globe are empowered to be bold at work — to navigate change and put their customers at the center of their leadership, strategy, and operations. Our unique insights are grounded in annual surveys of more than 700,000 consumers, business leaders, and technology leaders worldwide; rigorous and objective research methodologies, including Forrester Wave™ evaluations; and the shared wisdom of our clients. To learn more, visit Forrester.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903797204/en/
Contacts
Press contacts:
Hannah Segvich
hsegvich@forrester.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom